PubRank

Corrado D'Arrigo

Author PubWeight™ 19.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 2015 4.24
2 Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014 3.21
3 Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 2.88
4 Paget disease of the nipple: a multifocal manifestation of higher-risk disease. Cancer 2002 1.65
5 CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell 2005 1.61
6 Breast carcinoma in women age 25 years or less. Cancer 2002 1.50
7 Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene 2003 1.02
8 Human murine mammary tumour virus-like agents are genetically distinct from endogenous retroviruses and are not detectable in breast cancer cell lines or biopsies. Virology 2004 0.97
9 A viral aetiology for breast cancer: time to re-examine the postulate. Intervirology 2004 0.92
10 Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. Cancer Res 2005 0.90
11 Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC Laboratories. Appl Immunohistochem Mol Morphol 2017 0.82
12 Re. The significance of intra-mammary nodes in primary breast cancer. Eur J Surg Oncol 2001; 27: 707-708. Eur J Surg Oncol 2002 0.75
13 Pathogenesis of breast carcinoma. Int J Clin Pract 2004 0.75
14 Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in Immunohistochemistry. Appl Immunohistochem Mol Morphol 2016 0.75
15 Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance Characteristics. Appl Immunohistochem Mol Morphol 2017 0.75
16 Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry Biomarkers. Appl Immunohistochem Mol Morphol 2017 0.75